Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2025-04-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2023年限制性股票激励计划授予价格调整、首次授予部分第二类激励对象第一个归属期归属条件成就及部分限制性股票作废相关事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 restricted stock incentive plan of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It discusses the adjustment of the grant price, the achievement of vesting conditions for the first vesting period of the second category of incentive recipients, and the cancellation of some restricted stocks. The document includes detailed legal analysis, references to company board and shareholder meetings, regulatory compliance, and specific stock incentive plan terms. It is not a financial report, earnings release, or management discussion but a legal opinion related to stock incentive plan adjustments and compliance. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal compliance and regulatory disclosure document that does not constitute a financial report or other specific filing type.
2025-04-09 Chinese
江苏浩欧博生物医药股份有限公司关于2023年限制性股票激励计划首次授予部分第二类激励对象第一个归属期符合归属条件的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the fulfillment of conditions for the first vesting period of the second class of incentive recipients under the 2023 restricted stock incentive plan. It includes specifics about the stock incentive plan, vesting conditions, performance targets, approval procedures, and legal and financial advisor opinions. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is focused on the stock incentive plan and the vesting of restricted shares, which is a capital/financing related update. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing. Confidence is high due to the specificity and content of the document.
2025-04-09 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于江苏浩欧博生物医药股份有限公司2023年限制性股票激励计划首次授予部分第二类激励对象第一个归属期归属条件成就及作废部分限制性股票相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2023 Restricted Stock Incentive Plan of Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. It discusses the approval procedures, conditions for stock vesting, and cancellation of some restricted stocks. The document includes detailed financial and legal analysis, references to audit reports, and compliance with regulatory requirements. It is not a brief announcement but a comprehensive advisory report with substantive content on the stock incentive plan and related financial and governance matters. This fits the category of an Audit Report / Information (AR), as it is a standalone advisory report focusing on the application of accounting principles and regulatory compliance related to the stock incentive plan, rather than a full annual report or a simple announcement. FY 2023
2025-04-09 Chinese
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2022年限制性股票激励计划部分已授予但尚未归属的限制性股票作废相关事项之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain restricted stocks granted but not yet vested under a 2022 restricted stock incentive plan of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It contains detailed legal analysis, references to company board and shareholder meetings, regulatory compliance, and specific stock incentive plan details. It is not a financial report, earnings release, or management discussion. It is a standalone legal opinion related to corporate governance and stock incentive plan compliance. This fits best under the category of Audit Report / Information (AR) as it is a formal legal opinion document related to regulatory compliance and internal corporate actions, but not a full annual report or financial statement. The document length and content confirm it is not a brief announcement or certification, but a substantive legal report. FY 2024
2025-04-09 Chinese
江苏浩欧博生物医药股份有限公司2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024 Annual General Meeting Resolution Announcement" for Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2024 Annual Report, financial statements, profit distribution plan, and other corporate matters. The document primarily reports the official voting results and resolutions passed at the AGM. It does not contain the full annual report or financial statements themselves, but rather the outcomes of shareholder votes on these items. The document length is 3886 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-04-07 Chinese
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2024年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the procedural legality and validity of the 2024 Annual General Meeting (AGM) of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the convening, attendance, agenda, and voting procedures of the AGM, confirming compliance with relevant laws and company bylaws. The document does not contain financial statements or results but serves as a legal certification related to the AGM. This type of document is typically classified under AGM Information (AGM-R) as it pertains to materials shared or related to the Annual General Meeting.
2025-04-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.